← Leaderboards
Julie Kay Andersen
University Of Southern California
$26,330,372
Attributed
$32,092,408
Total exposure
23
Grants
16
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.4M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$40,648,484 · 24
By mechanism
R01$15,216,613 · 10
P01$10,909,991 · 4
RF1$8,778,996 · 3
RL1$2,173,770 · 1
P30$1,581,114 · 1
R21$1,067,000 · 2
Top collaborators
- Gordon J. Lithgow7 shared
- Malene Hansen3 shared
- Chaska Carlos Walton3 shared
- Chuankai Zhou3 shared
- Judith Campisi2 shared
- Gregory Mitsuo Chin2 shared
Most similar at University Of Southern California
Same institution · by research overlap
- Valter D. Longo$17,745,422
- Sean P. Curran$11,986,656
- Todd E Morgan$3,678,553
- Sebastian Brandhorst$600,967
- Caleb E Finch$20,916,232
Others in their field
Top investigators on “Alzheimer&Apos”
- Jose A Luchsinger · Columbia University Health Sciences$56,595,040
- Eric M Reiman · Banner Health$48,982,487
- Yadong Huang · J. David Gladstone Institutes$40,311,515
- Lindsay A. Farrer · Boston University Medical Campus$34,189,802
- David M Holtzman · Washington University$28,985,806
- Michael W Weiner · Northern California Institute Res &Educ$28,197,224
Research focus
Alzheimer&AposAgingOxidative StressCellsMitochondriaIn VivoIn VitroAge RelatedBrainLaboratoriesPreventProteinsFunctional DisorderParkinson DiseaseMediatingAffectNeuronsNerve DegenerationDopamineS DiseaseEventStructurePlayLaboratory Mouse
Grant awards (72)
A smart cell drug (SmaCD) delivery platform for mobile, targetable, and self-regulated combination therapy: a model project to rescue antibodies from Alzheimer's disease (AD) clinical trial failures$914,477
R01 · FY2025 · AG · contact PI
Novel mitochondria-to-lysosome crosstalk contributes to lysosomal dysfunction during aging$475,300
R01 · FY2025 · AG
Support and Preparation for an Alzheimer's Research Career$432,000
R25 · FY2025 · AG · contact PI
Research Development Core$793,030
P30 · FY2024 · AG · contact PI
Neuronal FXR as a potential therapeutic target for Alzheimer's disease$625,485
R01 · FY2024 · AG · contact PI
Novel mitochondria-to-lysosome crosstalk contributes to lysosomal dysfunction during aging$485,000
R01 · FY2024 · AG
A smart cell drug (SmaCD) delivery platform for mobile, targetable, and self-regulated combination therapy: a model project to rescue antibodies from Alzheimer's disease (AD) clinical trial failures$476,782
R01 · FY2024 · AG · contact PI
Cellular senescence and Alzheimer's disease$467,034
R01 · FY2024 · AG · contact PI
Support and Preparation for an Alzheimer's Research Career$432,000
R25 · FY2024 · AG · contact PI
Research Development Core$788,084
P30 · FY2023 · AG · contact PI
Neuronal FXR as a potential therapeutic target for Alzheimer's disease$624,323
R01 · FY2023 · AG · contact PI
A smart cell drug (SmaCD) delivery platform for mobile, targetable, and self-regulated combination therapy: a model project to rescue antibodies from Alzheimer's disease (AD) clinical trial failures$486,610
R01 · FY2023 · AG · contact PI
Novel mitochondria-to-lysosome crosstalk contributes to lysosomal dysfunction during aging$485,000
R01 · FY2023 · AG
Neuronal FXR as a potential therapeutic target for Alzheimer's disease$623,202
R01 · FY2022 · AG · contact PI
A smart cell drug (SmaCD) delivery platform for mobile, targetable, and self-regulated combination therapy: a model project to rescue antibodies from Alzheimer's disease (AD) clinical trial failures$534,821
R01 · FY2022 · AG · contact PI
New mechanistic insights into how the gut metabolite urolithin A extends lifespan and prevents AD$461,518
RF1 · FY2022 · AG · contact PI
Neuronal FXR as a potential therapeutic target for Alzheimer's disease$622,119
R01 · FY2021 · AG · contact PI
Cellular senescence and Alzheimer's disease$1,891,636
RF1 · FY2020 · AG · contact PI
Neuronal FXR as a potential therapeutic target for Alzheimer's disease$621,072
R01 · FY2020 · AG · contact PI
New mechanistic insights into how the gut metabolite urolithin A extends lifespan and prevents AD$3,414,407
RF1 · FY2018 · AG · contact PI
A temporal bioenergetic, metabolomics, and proteomic map of Alzheimer's disease in invertebrate models$3,011,435
RF1 · FY2017 · AG
Potential role of lysosomal ATP13A2 in cellular iron homeostasis$242,500
R21 · FY2017 · NS · contact PI
Pharmacology of Lifespan Extension$194,000
R01 · FY2017 · AG
Potential role of lysosomal ATP13A2 in cellular iron homeostasis$291,000
R21 · FY2016 · NS · contact PI
Environmental exposure and astrocytic senescence: novel link to PD?$242,500
R21 · FY2015 · ES · contact PI
Environmental exposure and astrocytic senescence: novel link to PD?$291,000
R21 · FY2014 · ES · contact PI
Mitochondrial Dysfunction in Aging and Disease$1,863,135
P01 · FY2011 · AG · contact PI
Subcellular localization of alpha-synuclein and its impact on neurodegeneration$432,135
RL1 · FY2011 · NS · contact PI
GLUTATHIONE DEPLETION AND MITOCHONDRIAL COMPLEX I DYSFUNCTION$403,975
P01 · FY2011 · AG · contact PI
2011 Oxidative Stress and Disease Gordon Research Conference$5,000
R13 · FY2011 · AG · contact PI
2011 Oxidative Stress and Disease Gordon Research Conference$2,000
R13 · FY2011 · AG · contact PI
Mitochondrial Dysfunction in Aging and Disease$1,920,859
P01 · FY2010 · AG · contact PI
GLUTATHIONE DEPLETION AND MITOCHONDRIAL COMPLEX I DYSFUNCTION$448,874
P01 · FY2010 · AG · contact PI
Subcellular localization of alpha-synuclein and its impact on neurodegeneration$432,135
RL1 · FY2010 · NS · contact PI
2011 Oxidative Stress and Disease Gordon Research Conference$50,000
R13 · FY2010 · AG · contact PI
Mitochondrial Dysfunction in Aging and Disease$1,577,939
P01 · FY2009 · AG · contact PI
Subcellular localization of alpha-synuclein and its impact on neurodegeneration$436,500
RL1 · FY2009 · NS · contact PI
GLUTATHIONE DEPLETION AND MITOCHONDRIAL COMPLEX I DYSFUNCTION$383,672
P01 · FY2009 · AG · contact PI
Iron dysregulation and Parkinson's disease$381,458
R01 · FY2009 · NS · contact PI
Mitochondrial function, TOR and Aging$356,564
P01 · FY2009 · AG · contact PI
Mitochondrial Dysfunction in Aging and Diseses$1,480,771
P01 · FY2008 · AG · contact PI
Subcellular localization of alpha-synuclein and its impact on neurodegeneration$436,500
RL1 · FY2008 · NS · contact PI
Role of GSH and MAO-B in PD-related mito dysfunction$425,378
R01 · FY2008 · NS · contact PI
Iron dysregulation and Parkinson's disease$381,458
R01 · FY2008 · NS · contact PI
GLUTATHIONE DEPLETION AND MITOCHONDRIAL COMPLEX I DYSFUNCTION$319,367
P01 · FY2008 · AG · contact PI
Mitochondrial Dysfunction in Aging and Diseses$1,356,808
P01 · FY2007 · AG · contact PI
Subcellular localization of alpha-synuclein and its impact on neurodegeneration$436,500
RL1 · FY2007 · NS · contact PI
Role of GSH and MAO-B in PD-related mito dysfunction$425,378
R01 · FY2007 · NS · contact PI
Iron dysregulation and Parkinson's disease$381,458
R01 · FY2007 · NS · contact PI
GLUTATHIONE DEPLETION AND MITOCHONDRIAL COMPLEX I DYSFUNCTION$265,048
P01 · FY2007 · AG · contact PI
ADMINISTRATION$105,093
P01 · FY2007 · AG · contact PI
Role of GSH and MAO-B in PD-related mito dysfunction$438,083
R01 · FY2006 · NS · contact PI
Iron dysregulation and Parkinson's disease$392,850
R01 · FY2006 · NS · contact PI
Gluthathione Depletion /Mitochondrial Complex I Dysfunct$370,049
R01 · FY2006 · AG · contact PI
Role of GSH and MAO-B in PD-related mito dysfunction$448,625
R01 · FY2005 · NS
ROLE OF IRON AND GLUTATHIONE IN PARKINSON'S DISEASE$291,000
R01 · FY2005 · AG
ROLE OF IRON AND GLUTATHIONE IN PARKINSON'S DISEASE$291,000
R01 · FY2004 · AG
EARLY IRON EXPOSURE, AGING, AND PARKINSON'S DISEASE$339,500
R01 · FY2003 · NS
MAO-B'S ROLE IN BRAIN AGING: NEED FOR INDUCIBLE MODELS$301,635
R01 · FY2003 · AG
ROLE OF IRON AND GLUTATHIONE IN PARKINSON'S DISEASE$291,000
R01 · FY2003 · AG
EARLY IRON EXPOSURE, AGING, AND PARKINSON'S DISEASE$339,500
R01 · FY2002 · NS
MAO-B'S ROLE IN BRAIN AGING: NEED FOR INDUCIBLE MODELS$292,849
R01 · FY2002 · AG
ROLE OF IRON AND GLUTATHIONE IN PARKINSON'S DISEASE$291,000
R01 · FY2002 · AG
ROLE OF THE GLUTATHIONE SYSTEM IN CELL STRESS AND AGING$213,943
P01 · FY2002 · AG
IRON, OXIDATIVE STRESS AND PESTICIDES IN PARKINSON'S$0
U54 · FY2002 · ES
EARLY IRON EXPOSURE, AGING, AND PARKINSON'S DISEASE$329,000
R01 · FY2001 · NS
ROLE OF IRON AND GLUTATHIONE IN PARKINSON'S DISEASE$291,000
R01 · FY2001 · AG
MAO-B'S ROLE IN BRAIN AGING: NEED FOR INDUCIBLE MODELS$275,533
R01 · FY2001 · AG
EARLY IRON EXPOSURE, AGING, AND PARKINSON'S DISEASE$50,000
R01 · FY2001 · NS
EARLY IRON EXPOSURE, AGING, AND PARKINSON'S DISEASE$286,125
R01 · FY2000 · NS
MAO-B'S ROLE IN BRAIN AGING: NEED FOR INDUCIBLE MODELS$267,509
R01 · FY2000 · AG
ROLE OF THE GLUTATHIONE SYSTEM IN CELL STRESS AND AGING$213,943
P01 · FY2000 · AG